Efficacy and safety of enzalutamide vs bicalutamide in European and North American men participating in the TERRAIN trial

Autor:	Benoit Baron, Neal D. Shore, David Forer, D. Robert Siemens, Nahla Hasabou, Axel Heidenreich, Steve van Os, Laurence Klotz, Simon Chowdhury, Fong Wang, Arnauld Villers
Rok vydání:	2016
Předmět:	Oncology Cancer Research medicine.medical_specialty Bicalutamide business.industry chemistry.chemical_compound chemistry Internal medicine medicine Enzalutamide In patient business human activities medicine.drug
Zdroj:	Journal of Clinical Oncology. 34:5063-5063
ISSN:	1527-7755 0732-183X 0128-8911
Popis:	5063Background: In the TERRAIN trial (NCT01288911), enzalutamide (ENZA) significantly increased progression-free survival (PFS) compared to bicalutamide (BIC) in patients (pts) with progressive met...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::75757067012f4be916526e93e0b1e903 https://doi.org/10.1200/jco.2016.34.15_suppl.5063 Zobrazit plný text záznamu